Frederick Vogt | Interim President and CEO |
Igor Bilinsky | COO |
Jim Zigler | SVP, Commercial |
Friedrich Finckenstein | CMO |
Jean-Marc Bellemin | CFO |
Madan Jagasia | SVP of Medical Affairs |
Sara Pellegrino | VP, Investor and Public Relations |
Michael Yee | Jefferies |
Mark Breidenbach | Oppenheimer |
Benjamin Burnett | Stifel |
Nick Abbott | Wells Fargo |
Colleen Kusy | Baird |
Welcome to the Iovance Biotherapeutics Second Quarter 2021 Financial Results. My name is Josh, and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions].